Member Info for PL75

Meaningful therapeutic levels to quote Alan. Sounds like a product ready for market when considered alongside the complete lack of cardiotoxicity and significantly reduced side effects. Have a couple more goes at DE to see if an MTD can be reached based on the data so far and bosh out 1b & 2 = $5bn market in the bag. Simples.

It didn’t work. Unlike AVA6k, which does.

Who is ‘the market’? Current retail investors, so of course a bunch of idiots sell out delighted with their 10% and of course there isn’t enough sustained buying pressure to 10x overnight. At the moment we’re appealing to venture capitalists like Sequoia Flooring and Hanna Barbara, not to major IIs, pension funds etc. The story here will emerge over time. Enjoy accumulating while you can. I don’t give two toots about FUD, after all it works so value will out eventually - either like a bolt from a deal or from a steady grind to market. What will be will be… and no end of twats can stop it.

I clicked post message, now what?

The main problem on this board is your repeated inability to click reply.

RAH - marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration, not nil side effects. I love a good ramp, just yesterday I was flinging £20 about as it’s a bargain, but best not to post things that aren’t true.

It undermines the truth - marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. That is a phenomenal statement with twice the dox.

BV, agreed. They’re stunned by how well it’s working. They planned for 3 or 4, now they’re planning 2 more escalations. As rippers has said, there is absolutely no negative in that at all, especially when they’re awash with cash. That’s cash they raised in a very difficult market, there’s a reason they could do that and turn down even more... It works (tm).

Licence AVA6k to fund the next one or vice versa. Meh. Whatever works best. Our understated conservative broker note suggests licensing and they tend to have the inside nod. There’s a pipeline, we’re sat on cash, more cash from Dx coming in, science day arriving when a few more IIs might fancy chucking more cash in. Not sure the order of licence versus in house matters too much if the deal is right for the long term. As noted it’s an old video, the decision to get all that cash could have been based on the emerging phase 1 data and a strong desire to have that $5bn to themselves

It’s obviously a teeny bit above the current market cap, but £20 isn’t outlandish when converted to billions and compared to other deals. Looking forward to hearing more at the science day. Any further hints towards It Works (tm) and we continue the inevitable march towards a deal - be that a juicy licence or a takeover. Hopefully a licence to provide the cash for AVA6k. With the FDA interest, I’m sure Nasdaq and a more reflective market cap would be on the way. Exciting times ahead

I wouldn’t accept. Who would accept the first offer? I’d love £8 to turn up as it would sharpen the minds of a few other companies with a war chest. Let’s settle on £20 and we can all go home. Alan has referenced Ablynx and so I believe his exit plan is selling out. I can’t see him cashing out below that deal and especially if the results are as promising as we all think. So, $5bn+ for starters.

Top 5 tarts

I asked ChatGPT to write a boring 500 word essay on technical analysis and why it can't predict share price movements after news is released. I can see the green box tedious failed gambler has already responded. Wonder which response is duller. You might find more joy in speaking to ChatGPT in future BV.

>>>>>>>>>>>>>>>>>>>>>>>>>>>
Technical analysis is a method of evaluating securities by analyzing statistics generated by market activity, such as past prices and volume. The goal of technical analysis is to identify patterns and trends that can indicate future activity. However, technical analysis is not able to predict share price movements after news is released, because it is based on historical data and does not take into account fundamental factors such as a company's financial health or industry conditions.

One of the main reasons that technical analysis is not able to predict share price movements after news is released is that it is based on historical data. Technical analysts use charts and other tools to identify patterns and trends in past market activity, but these patterns and trends may not be indicative of future activity. For example, a stock may have had a strong upward trend in the past, but this does not mean that it will continue to rise in the future.

Another reason that technical analysis is not able to predict share price movements after news is released is that it does not take into account fundamental factors such as a company's financial health or industry conditions. Technical analysis is based solely on market activity, whereas fundamental analysis looks at a company's financial statements, management, and other factors to assess its value. Fundamental analysis can help investors identify companies that are undervalued or overvalued and make more informed investment decisions.

In addition, news and events can significantly affect the market and its stock prices. Technical analysis is not designed to take into account events that may happen in the future, such as earnings reports, product launches or political decisions. While it may be able to identify patterns and trends in the market, it cannot predict the impact that these events will have on stock prices. It is important to note that news and events can also change the trends and patterns that technical analysts are looking for, making the analysis less accurate.

In conclusion, technical analysis is a method of evaluating securities that is based on historical data and market activity. While it can be useful in identifying patterns and trends, it is not able to predict share price movements after news is released. This is because technical analysis does not take into account fundamental factors such as a company's financial health or industry conditions, and also news and events that may happen in the future can change the trend and patterns that technical analysts are looking for.

I rely on my neighbour for my scientific evidence, after all, he downed a pint of it. He said it’s therapeutic. He also said it’s delicious. If anyone’s keen they serve it in the wetherby whaler.

They’ve included Abakta a few times, so they’re obviously keen to follow the story

Woah woah woah. The one thing you DON’T EVER DO is question the integrity of Sujood. Never wrong.

I’ve heard all I need to. Thanks for your replies Expect. As you’ve asked, my opinion, based on the data from biopsies is that it works and that the current share price is an absolute steal, especially given all the other strings to its bow. My advice, read the information from google you’re keen to ignore and form your own opinion, you gormless twat xx

Sorry. I’ve thoroughly enjoyed the relentless pursuit of answers that have confirmed the obvious. Baseless nonsense from an idiot.

Good advice. Anyway, congrats on making it on the leaderboard. Rippers must be quaking in his boots, a new rec farmer is in town.

Amazing. So you bought in with no research based on it being a 500% higher price than before they raised a bunch of cash, bought a profitable Dx company, entered the clinic and have had unequivocal data demonstrating it works, raised another wad of cash via non dilutive means - and you think it’s overvalued because the LFD wasn’t commercialised in the face of govt corruption? Just checking….

Thanks for confirming you’re utterly clueless. Do some research before buying. What you’ve done is ‘totally the wrong way to invest’. Muppet.

Who says I’m not on a yacht? Why does investing here equate to being a sheep? It’s obvious you’ve lost money, you didn’t need to share that.

‘This is totally the wrong way to invest.’

What’s the right way? Buy in at £1.50 with the opinion the share price will fall to 90p?

Thanks Prof, but this thread is about the recent RNS so best stay on topic. We’ll revisit the sea lion’s prophetic ramblings in a few decades time - by then he might have finished his lengthy boring thesis on it. Meanwhile, we’re trying to establish what Expect thinks is the right way to invest.

Glad you agree it works. So… moving on…. You’re not here to save us, but…

‘This is totally the wrong way to invest.’

What’s the right way? Buy in at £1.50 with the opinion the share price will fall to 90p?